BioMarin Pharma has decided not to divest its haemophilia A gene therapy Roctavian, which has struggled to build much traction in the market, but is reining back its ambitions for the business.

BioMarin Pharmaceutical (BMRN) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. Research shows ...

BioMarin Pharmaceutical (BMRN ... A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock ...

BioMarin Pharmaceutical (BMRN ... A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock ...

A significant part of BioMarin’s growth strategy involves Voxzogo, which has shown strong sales performance. Although facing competition, Voxzogo stands out due to its high compliance rate ...

Wedbush analyst Yun Zhong maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of $94.00. Discover outperforming stocks and invest smarter ...

BioMarin Pharmaceutical (BMRN) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. Studies have ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...